William S. Reardon is Director at SYNTA PHARMACEUTICALS CORP (SNTA). They have made 12 open-market trades across 7 companies since 2006, most recently 2021-04-06.
CIK 0001212646
12 open-market purchases totalling $161K since 2006, never a sale. Across 7 scored buys the stock is up 0.6% at ninety days, and 1.8 points behind the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 0% | 14% | 14% |
| Avg Move | -17.2% | -1.3% | +0.6% |
| Alpha | -13.4% | -1.9% | -1.8% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| THW | BUY | 2021-02-25 | 2021-03-01 | $17.14 | $25K | -6.9% | -7.7% | -2.9% |
| THQ | BUY | 2021-02-25 | 2021-03-01 | $20.85 | $25K | -2.1% | +0.4% | +8.2% |
| HQL | BUY | 2014-06-30 | 2014-07-01 | $19.75 | $4K | -17.3% | -0.3% | -0.3% |
| SNTA | BUY | 2013-11-13 | 2013-11-15 | $3.75 | $50K | N/A | N/A | N/A |
| IDRA | BUY | 2013-09-16 | 2013-09-17 | $1.82 | $25K | -30.0% | +0.0% | +0.0% |
| HQH | BUY | 2012-03-09 | 2012-03-12 | $15.86 | $10K | -17.1% | -0.9% | -0.9% |
| HQL | BUY | 2012-03-09 | 2012-03-12 | $13.27 | $10K | -17.3% | -0.3% | -0.3% |
| IDRA | BUY | 2008-01-02 | 2008-01-04 | $11.29 | $2K | -30.0% | +0.0% | +0.0% |
| IDP | BUY | 2007-10-01 | 2007-10-03 | $7.61 | $2K | N/A | N/A | N/A |
| IDP | BUY | 2007-07-02 | 2007-07-05 | $5.58 | $2K | N/A | N/A | N/A |
| IDP | BUY | 2007-04-03 | 2007-04-05 | $7.65 | $4K | N/A | N/A | N/A |
| IDP | BUY | 2006-07-06 | 2006-07-07 | $3.36 | $3K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| IDP |
| 4,008 |
| — |
| Total | $338K |
Shares reported on the most recent Form 4, priced at the 2021-04-08 close. 3 holdings could not be priced and are excluded from the total.